Mural Oncology's stock plummeted 57% after halting the Phase 3 ARTISTRY-7 trial for nemvaleukin alfa. Click here to read an ...
REDWOOD CITY, Calif., April 01, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced ...
The details of Dr. Reneau’s presentations are as follows ... dose and would have met the eligibility criteria for the ongoing registrational Phase 3 clinical trial based on ≥1 and ≤3 prior therapies, ...
Durability Results from BOND-003 data will be presented as a late breaker as part of AUA’s Practice-changing, Paradigm-shifting Clinical Trials ...
Differential Response Between African Americans and Non-African Americans with Resistant Hypertension to MANP, a Novel ...
EpimAb Biotherapeutics, a clinical stage biotechnology company specializing in the development of bispecific antibodies and T ...
Semaglutide, a glucagon-like peptide 1 (GLP-1) agonist, significantly improved maximal walking distance in people with ...
Additional data from the MDNA11 ABILITY-1 trial to be presented at the Annual Meeting Pre-clinical data on Medicenna’s first-in-class Masked and Tumor Targeted Bifunctional anti-PD1-IL2 Superkine, ...
The role of AI in supply chain management proved to be the focal issue at the recent 2025 Clinical Trial Supply Europe ...
Session Date and Time: Monday, April 28, 2:00 - 5:00 p.m.
PHILADELPHIA, PA — Cabaletta Bio, Inc. (Nasdaq: CABA) has announced its financial results for the fourth quarter and full ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback